CTIS2023-509484-24-00招募中1 期
FK/SC-VLS/23
Farmak JSC0 个研究点目标入组 36 人开始时间: 2024年1月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to compare availability in the body of the active substance nicotine as well as patch adhesion of the newly developed patch LTS Nicotine TTS (18.6 cm2) vs. Nicotinell® (21 mg/24 h) in healthy smokers after single patch applicatiobioequivalence and patch adhesion trialtherapeutical indication not studiedMedDRA version: 20.0Level: PTClassification code: 10057852Term: Nicotine dependence Class: 100000004873MedDRA version: 20.0Level: PTClassification code: 10053325Term: Smoking cessation therapy Class: 100000004865MedDRA version: 20.0Level: LLTClassification code: 10008374Term: Cessation of smoking Class: 10041244CTIS2023-503548-14-00TS LOHMANN Therapie-Systeme AG72
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55
进行中（未招募）
1 期
Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANECTIS2023-505945-19-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting96
进行中（未招募）
1 期
Bioequivalence of Oxazepam 50 mg Orodispersible Tablets Versus Seresta® 50 mg Tablets in Healthy Subjects.CTIS2022-501135-16-00aboratorios Lesvi S.L.28
招募中
1 期
FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics, and anti-tumors efficacy of the glyco-humanized polyclonal antibody XON7 in patients with advanced or metastatic solid tumors.CTIS2023-505266-29-00Xenothera246